CRISPR/Cas9-mediated gene manipulation to create single-amino-acid-substituted and floxed mice with a cloning-free method. by Ma, Xiaolong et al.
UC San Diego
UC San Diego Previously Published Works
Title
CRISPR/Cas9-mediated gene manipulation to create single-amino-acid-substituted and 
floxed mice with a cloning-free method.
Permalink
https://escholarship.org/uc/item/7qj934n0
Journal
Scientific reports, 7(1)
ISSN
2045-2322
Authors
Ma, Xiaolong
Chen, Chao
Veevers, Jennifer
et al.
Publication Date
2017-02-08
DOI
10.1038/srep42244
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
1Scientific RepoRts | 7:42244 | DOI: 10.1038/srep42244
www.nature.com/scientificreports
CRISPR/Cas9-mediated gene 
manipulation to create single-
amino-acid-substituted and floxed 
mice with a cloning-free method
Xiaolong Ma1,2, Chao Chen2, Jennifer Veevers2, XinMin Zhou1, Robert S. Ross2,3, Wei Feng2 & 
Ju Chen2
Clustered regulatory interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 
(Cas9) technology is a powerful tool to manipulate the genome with extraordinary simplicity and 
speed. To generate genetically modified animals, CRISPR/Cas9-mediated genome editing is typically 
accomplished by microinjection of a mixture of Cas9 DNA/mRNA and single-guide RNA (sgRNA) into 
zygotes. However, sgRNAs used for this approach require manipulation via molecular cloning as well as 
in vitro transcription. Beyond these complexities, most mutants obtained with this traditional approach 
are genetically mosaic, yielding several types of cells with different genetic mutations. Recently, a 
growing body of studies has utilized commercially available Cas9 protein together with sgRNA and a 
targeting construct to introduce desired mutations. Here, we report a cloning-free method to target 
the mouse genome by pronuclear injection of a commercial Cas9 protein:crRNA:tracrRNA:single-strand 
oligodeoxynucleotide (ssODN) complex into mouse zygotes. As illustration of this method, we report 
the successful generation of global gene-knockout, single-amino-acid-substituted, as well as floxed 
mice that can be used for conditional gene-targeting. These models were produced with high efficiency 
to generate non-mosaic mutant mice with a high germline transmission rate.
The clustered regulatory interspaced short palindromic repeat (CRISPR)/CRISPR-associated protein 9 (Cas9) 
system is a powerful and widely used editing tool for the direct manipulation of the mouse genome in zygotes. It 
has provided an extremely efficient method for the generation of genetically modified mice to elucidate the func-
tions of genes in development and disease1–3.
The CRISPR/Cas9 system was initially described as an acquired prokaryotic immune defense system con-
sisting of a Cas9 nuclease and two small RNAs: CRISPR RNA (crRNA), which acts as a guide for gene targeting, 
and trans-activating crRNA (tracrRNA), which binds to crRNA and forms a ribonucleoprotein complex with 
Cas9 to direct sequence-specific Cas9 double-stranded (ds) DNA cleavage4–6. Given its simplicity, the CRISPR/
Cas9 system has been adopted for robust genome editing by engineering the dual-crRNA:tracrRNA as a chimeric 
single guide RNA (sgRNA)4,7. Currently, the most commonly used approach for generating mutant mice with 
the CRISPR/Cas9 system is to microinject Cas9 mRNA and sgRNA, or their expression plasmid into zygotes8–10. 
However, this approach harbors a number of disadvantages11. First, sgRNAs used in this approach require manip-
ulation via molecular cloning as well as in vitro transcription. Second, most mutants produced with this cur-
rent method are genetically mosaic, leading to cells carrying a variety of different insertion or deletion (indel) 
mutations. This in turn complicates germline transmission of the genetic variant, and can also make phenotypic 
analysis of founder embryos and mice more complex. Furthermore, increasing evidence has demonstrated that 
methodology using direct delivery of Cas9 protein can be more efficient than the use of Cas9 mRNA in the gen-
eration of non-mosaic mutant mice1,2,12.
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To overcome the target vector construction and in vitro RNA transcription required for sgRNA, a recent study 
used crRNA and tracrRNA in combination with commercially available Cas9 protein and a regular gene targeting 
vector, to generate knock-in mice2. In our current study we report a method that capitalized on a cloning-free 
CRISPR/Cas9 system using commercial Cas9 protein combined with chemically synthesized crRNA, tracrRNA, 
and single-strand oligodeoxynucleotides (ssODNs). This system allowed us to consistently obtain high-efficiency 
editing of multiple genes in the mouse, and successfully generate non-mosaic mutant mouse models with a variety 
of editing schemes, including, frame-shift indel mutations, single-amino-acid substitutions, and LoxP-inserted 
conditional alleles. Taken together, our method is a simple, cloning-free, and highly efficient technique, which 
accelerates our ability to produce rapid mouse genome editing in vivo.
Results
Generation of gene-knockout mice. The double-strand breaks (DSBs) induced by the CRISPR/Cas9 sys-
tem stimulate DNA repair by at least two distinct mechanisms, non-homologous end joining (NHEJ) and homol-
ogy-directed repair (HDR)13,14. NHEJ is error-prone and introduces unpredictable patterns of insertions and 
deletions, which can lead to disruption of the protein-coding capacity of a defined locus. To investigate whether 
gene-knockout mice can be efficiently generated by direct pronuclear injection of a Cas9 protein:crRNA:tracr-
RNA complex into mouse zygotes (Fig. 1), we designed crRNA targeting alpha kinase 2 exon 3, which contains 
the start codon (Fig. 2a). Using the T7 endonuclease 1 (T7E1) assay to detect on-target CRISPR/Cas9 events, we 
found that six out of 16 (37.5%) mice contained indel mutations (Fig. 2b). Subsequent sub-cloning of flanking 
regions surrounding the crRNA targeting site identified three mice with frameshift mutations (Fig. 2c). Each of 
these mice appears to be non-mosaic as they contain only wildtype and one type of mutant allele.
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Figure 1. Schematic overview of the study. A cloning-free CRISPR/Cas9 system using commercial Cas9 
protein combined with chemically synthesized CRISPR RNA (crRNA), trans-activating crRNA (tracrRNA), 
with or without single-strand oligodeoxynucleotides (ssODNs) generated non-mosaic mutant mouse models 
with a variety of editing schemes, including, frame-shift insertion or deletion (indel) mutations, single-amino-
acid substitutions, and LoxP-inserted conditional alleles.
Mouse gene
No. of mice 
at wean
Amino acid 
replacement Mutation sequence
Correct knock-
in efficiency
SYNE1 17 R257H CGG- > CAT 35%
SYNE1 9 W463D464- > AA TGGGAC- > GCGGCC 33%
SYNE1 15 E646K GAG- > AAG 53%
NEXN 6 R274C CGT- > TGT 33%
NEXN 5 G645DEL GGA- > – 40%
TAX1BP3 14 I33T ATT- > ACT 50%
FLNC 5 S1625L TCG- > TTG 60%
TLN 3 L432G CTT- > GGT 67%
Table 1. Generation of mutant mice by Cas9 protein:crRNA:tracrRNA complex injection.
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Generation of single amino-acid-substituted mice. Single amino-acid substitutions frequently cause 
genetic diseases in man and thus recapitulation of these variants is used to produce mouse models of disease. To 
investigate whether mice with single amino-acid-substitutions could be generated easily using the same approach 
noted above, we aimed to generate founder mice harboring an arginine (257) to histidine amino acid substitution 
in the Nesprin-1α 2 (SYNE1) gene (Figs 1 and 3a). We injected a mixture of 30 ng/μ L Cas9 protein, 0.6 pmol/μ 
L SYNE1-R257H crRNA, 0.6 pmol/μ L tracrRNA, and 20 ng/μ L ssODN into the pronuclei of zygotes. In order 
to quickly screen for correctly targeted mice, we designed mutation-specific primers with a site-specific vari-
ant sequence at the 3′ terminus of the forward primer, as shown in Fig. 3b. We found six of 17 newborn mice 
contained the correct gene variant allele (Fig. 3c). The HDR efficiency of the targeted mutation by Cas9 pro-
tein:crRNA:tracrRNA complex injection was thus 35%. The genotypes of PCR-positive mice were confirmed by 
sequencing the six individual sub-clones (Fig. 3d). We found that the six correctly targeted mice contained only 
two types of alleles, compared with multiple alleles as reported by Cas9 mRNA/sgRNA injection15, indicating that 
the founders are heterozygous mice rather than chimeras.
To investigate germline transmission of the variant alleles to the F1 generation, we backcrossed F0 knock-in 
mice with wildtype C57/B6 mice. We tested three different variant lines using PCR and subsequent sequencing, 
and found that all F0 mice showed successful germline transmission with an average efficiency of 52.8% (ranging 
from 36% to 71% among different founders). A representative genotyping screen of offspring from one founder 
(designated #13) is provided (Fig. 3e). Consistent with only two types of alleles in the founders, these results indi-
cate that the founders are heterozygous mice rather than chimeras. We have so far successfully generated eight 
different variant mice using this method (Table 1).
Finally, we investigated off-target cleavage in the CRISPR/Cas9 generated mice produced with our methodol-
ogy. This has been a serious problem associated with CRISPR/Cas9-mediated genome editing techniques in the 
past11,16,17. Here we tested the top five predicted off-target sites for mutagenesis using the CRISPR Design (MIT) 
website18 (Fig. 4a). A region flanking each predicted off-target site was amplified by PCR from wildtype and two 
mutant founders (Fig. 4b). The same molecular size band resulted from all samples, indicating there were no large 
deletions flanking the sites. Furthermore, we confirmed the sequence flanking the predicted off-target sites by 
3’ UTR 5’ UTR 1 11 12 13 10 97 865 4 3 2 
5’…aggtcagcccaagccaGAGGTGACTTGGTATAAGAAtggtcaagccatagacttggg…3’ 
3’…tccagtcgggttcggtctccactgaaccatattcttaccagttcggtatctgaaccc…5’ 
200 bp 
500 bp Uncut 
Cut 
a 
b 
c 
5’…aggtcagcccaagccaGAGGTGACTTGGTATAAGAAtggtcaagccatagacttggg…3’ 
5’…aggtcagcc-------------------------------caagccatagacttggg…3’  34 bp 
WT 
#4 
5’…aggtcagcccaagccaGAGGTGACTTGGT-----------caagccatagacttggg…3’  11 bp  
5’…aggtcagcccaagccaGAGGTGACTTGGTACTAAGAAtggtcaagccatagacttggg…3’  +1 bp 
#13 
#15 
WT 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 # 1 M 
Figure 2. Generation of alpha kinase 2-knockout (ALPK2-KO) mice. (a) Sequence of CRISPR RNA (crRNA, 
red) to target the Cas9 nuclease to a region of exon 3 in the ALPK2 mouse gene. The protospacer adjacent 
motif (PAM) is shown in green. (b) CRISPR/Cas9-mediated genomic modification was revealed by the T7 
endonuclease 1 (T7E1) assay. Six of 16 founder mice contained cleavage products. M, molecular marker; WT, 
wildtype. (c) Subsequent sub-cloning of flanking regions surrounding the crRNA targeting site (n = 6 sub-
clones/mouse) identified three mice (#4, #13, and #15) with frameshift mutations. In mouse #15, the insertion 
nucleotide is underlined in blue.
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3’ UTR 5’ UTR 1 
5’…ttctcgctttgaagactgGCTGGAGGTTTCAGAAAGGAcggctgctttccccagttctt…3’ 
3’…aagagcgaaacttctgaccgacctccaaagtctttcctgccgacgaaaggggtcaagaa…5’ 
a 
ATG 
2 4 3 5 6 87 9 10 11 12 13 14 15  16  
STOP 
b 
d 
H 
A A A G G A C G G C T G C T T 
A A A G G A C A T C T G C T T 
5’-TGGCTGGAGGTTTCAGAAAGGACGGCTGC……AGAGCAGTGACGATTTTAATTGAAGATTAGC-3’ 
WT 5’-TGGAGGTTTCAGAAAGGACGG-3’ 
MUT 5’-TGGAGGTTTCAGAAAGGACAT-3’ 
3’-GTCACTGCTAAAATTAACTTCTAATCG-5’ 
3’-ACCGACCTCCAAAGTCTTTCCTGCCGACG……TCTCGTCACTGCTAAAATTAACTTCTAATCG-5’ 
Reverse 
Forward 
c WT 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 17 
WT 
R257H 
F0    # 1 
e WT 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 17 
WT 
R257H 
F1 18 # 1 
WT 
KI 
#13 
R 
Figure 3. Generation of Nesprin-1α2 R257H knock-in mice. (a) Sequence of CRISPR RNA (crRNA, red) to 
target the Cas9 nuclease to the arginine (R) 257 region in exon 4 in the Nesprin-1α 2 (SYNE1) mouse gene. The 
protospacer adjacent motif (PAM) is shown in green. (b) Design of the mutation-specific primers to detect the 
R257 to histidine (H) amino acid substitution. (c) PCR screening using mutant-specific primers identified six 
of 17 newborn mice contained the correct gene variant allele. (d) Sub-cloning sequencing shows an individual 
clone has either wildtype (WT) or R257H knock-in (KI) alleles. A representative sequencing analysis of one 
founder (#13) of the six PCR-positive mice is shown. (e) Germline transmission analysis of the variant alleles 
to the F1 generation was achieved by backcrossing F0 knock-in mice with wildtype C57/B6 mice. All F0 mice 
showed successful germline transmission with an average efficiency of 52.8% (ranging from 36% to 71% among 
different founders, n = 3). A representative genotyping screen of offspring from one founder (#13) is shown.
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sequencing six individual clones of each founder (Fig. 4c). The sequencing data confirmed no off-target cleavage, 
suggesting that genome editing by Cas9 protein:crRNA:tracrRNA complex injection is highly specific.
Generation of conditional knockout mice. We further investigated whether mice could be generated 
using this one-step approach by insertion of two LoxP sites into the same allele of the paxillin gene (Fig. 1). Use 
of this facilitated methodology would greatly accelerate the time to produce a model that could be used to condi-
tionally manipulate a gene of choice. We designed a crRNA targeting the paxillin gene intron 5 (left) and a crRNA 
targeting paxillin intron 6 (right), as well as the corresponding LoxP site oligos with 60 bp homology sequences 
on either side surrounding each Cas9-mediated DSB (Fig. 5a). Mutation-specific PCR analysis identified that two 
out of 12 (17%) mice had either left (#10) or right (#2) LoxP insertion (Fig. 5b). One pup (#5) however, was shown 
to have successful insertion of both LoxP sites in the paxillin allele (Fig. 5b). The precise integration of LoxP sites 
into the same allele was confirmed by sequencing PCR products generated from DNA from this model (Fig. 5c). 
To demonstrate that the floxed allele is indeed functional, we crossed the paxillin floxed mice with germline 
deleter Cre mice (Sox2-Cre)19. As shown in the Fig. 5d, the DNA between the two LoxP sites was deleted by Cre 
recombinase.
Discussion
The CRISPR/Cas9 system is proving to be a powerful yet simple tool to manipulate the genome for the gen-
eration of genetically modified animals. In this study, we report the successful generation of both single 
amino-acid-substituted and floxed alleles, using a simplified, cloning-free CRISPR/Cas9-mediated method. Our 
system offers an advantage over more traditional methods since it generates non-mosaic mutant mouse models, 
and does so without CRISPR/Cas9 vector construction or in vitro RNA transcription manipulation.
In each of our mutant mice lines generated by pronuclear injection of a Cas9 protein:crRNA:tracrRNA com-
plex, with or without ssODN, only two types of alleles resulted with a high frequency of germline transmission 
(~50%), supporting the notion that founders are germline heterozygous, and not chimeric. In our study, we also 
did not observe any detectable off-target effects in the top five predicted off-target sites for mutagenesis using 
Cas9 protein:crRNA:tracrRNA-mediated genome editing, which is consistent with other methods2. This suggests 
that it is feasible to achieve low off-target effects through injection of Cas9 protein into the pro-nuclei of mouse 
zygotes. No chimerism and detectable off-target effects observed using our approach may reflect that the Cas9 
protein has a relatively shorter half-life in embryos than Cas9 mRNA20. This phenomenon is also consistent with 
the finding that a Cas9 protein-RNA complex was rapidly degraded in cultured cells21,22. The rapid degradation 
of Cas9 protein may be advantageous in avoiding side effects of Cas9 nuclease activity. Another possibility is 
that it takes time for Cas9 mRNA to translate into Cas9 protein23. When Cas9/sgRNA complexes translocate to 
the nucleus with the function of the nuclear localization signal, the donor DNA may be transferred in a delayed 
fashion24. In this scenario, repair of DSBs by NHEJ could already be in process prior to the arrival of donor DNA 
at the target site.
In summary, we report a novel method for the highly efficient generation of non-mosaic mutant mouse mod-
els with indel mutations, single-amino-acid substitutions, and LoxP-inserted alleles, through one-step injection 
of commercially available Cas9 protein combined with chemically synthesized crRNA and tracrRNA. This simple, 
customizable and ready-to-use genome editing system accelerates our ability to produce rapid mouse genome 
editing in vivo.
Off-target sequence PAM Score Mismatches Locus 
1 GTTGGAGATTTCAGAAAGGA CGG 6.7 2MMs [2:8]  chr3:-138
601567 
2 TCTCGAGGTTTCAGAAAGGA AGG 5.7 2MMs [1:4]  chr10:+11
1749408 
3 GCTGGAGGTGACAGAAAGGA CAG 2.7 2MMs [10:11] chr12:+23
230496 
4 GATGCAGATTTCAGAAAGGA CAG 2.5 3MMs [2:5:8] chr13:-34
464320 
5 GATGGAGTTCTCAGAAAGGA AAG 2.5 3MMs [2:8:10] chr3:-151
692054 
a 
b 
c 
WT Founder #12 Founder #13 
1 2 3 4 5 1 2 3 4 5 1 2 3 4 5OT # 
G T T G G A G A T T T C A G A A A G G A C G G OT #1 
T C T C G A G G T T T C A G A A A G G A A G G 
G C T G G A G G T A G C A G A A A G G A C A G 
G A T G C A G A T T T C A G A A A G G A C A G 
A T G G A G T T T C C A G A A A G G A A A G G 
OT #2 
OT #3 
OT #4 
OT #5 
Figure 4. Analysis of off-target candidates at predicted sites in the mouse genome. (a) The top five predicted 
off-target sites for mutagenesis. The mismatch (MM) sequence is labeled in red. PAM, protospacer adjacent 
motif. (b) PCR products flanking each predicted off-target (OT) site (#1–5) in wildtype (WT) and mutant 
founder (#12 and #13) mice. (c) Sub-cloning sequencing (n = 6 sub-clones/mouse) confirmed no off-target 
cleavage. A representative sequencing analysis of one founder (#13) is shown.
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Methods
CRISPR target sequence design. Guide sequences for CRISPR/Cas9 injection were designed as previ-
ously detailed18. The target sequence preceding the protospacer adjacent motif (PAM) was obtained from the exon 
region of the indicated genes.
Chemical synthesis of crRNA, tracrRNA, and ssODN. The crRNA and tracrRNA were designed as 
previously reported2, chemically synthesized, and RNase-Free HPLC purified by Integrated DNA Technologies 
(Coralville, IA, USA). Single-strand ODN was chemically synthesized and standard desalted by Integrated DNA 
Technologies (Coralville, IA, USA). All sequences are listed in Table 2.
Cas9 proteins. Recombinant Cas9 proteins were obtained from New England BioLabs (Cat #M0386S) 
(Thousand Oaks, CA, USA).
5’…TGTTAGGTCTTGTCTGTTCACTCTG AGGTAGGG…3’ ataact......agttat 
Exon 5 Exon 7
Left Oligo 
Donor 
5’…TGTTAGGTCTTGTCTGTTCACTCTGAGGTAGGG…3’ 
5’…GTTGATGGCTGCTCTTGCTGGAGGAGGGTGTGT…3’ 
5’…GTTGATGGCTGCTCTTGCTGGAGGA GGGTGTGT…3’ ataact......agttat Right Oligo 
Donor 
884 bp 
Left LoxP 
Insertion 
Right LoxP 
Insertion 
a 
b 
c 
LoxP 
LoxP 
# 1 2 3 4 5 6 7 8 9 10 11 12 
Exon 6
Cre+ Cre- 
F/+ F/+ 
300 bp 
500 bp 
1000 bp 
d 
F/+ F/+ 
Figure 5. Generation of conditional knockout mice. (a) Schematic illustration to generate a conditional allele 
of the paxillin gene by insertion of two LoxP sites. The sequences of CRISPR RNA (crRNA) to target the Cas9 
nuclease to intron 5 (left) and intron 6 (right) are shown in red. The protospacer adjacent motif (PAM) is shown 
in green. In the oligo donor sequence, the LoxP site is highlighted in yellow. (b) PCR screening using mutant-
specific primers identified one (#5) of 12 mice had successful insertion of both LoxP sites in the paxillin allele. 
(c) Sub-cloning sequencing confirmed the precise integration of LoxP sites in mouse #5. (d) PCR genotyping of 
paxillin floxed (F) mice crossed with Sox2-Cre mice using primers spanning the two LoxP sites. The presence 
of an amplified DNA fragment (440 bp) indicates that DNA between the two LoxP sites was deleted by Cre 
recombinase.
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Microinjection of zygotes. All animal studies were performed in accordance with the Guide for the Care 
and Use of Laboratory Animals, published by the National Academies Press (US), 2011, 8th Edition, and accord-
ing to protocols approved by the Institutional Animal Care and Use Committee at the University of California, 
San Diego. The protocol describing pronuclear microinjection is provided on the University of California, San 
Diego Transgenic Mouse Core website (https://healthsciences.ucsd.edu/research/moores/shared-resources/
transgenic-core/services/Pages/pronuclear-injection.aspx). Briefly, Cas9 proteins, crRNA and tracrRNA, with or 
without ssODN were diluted and mixed in IDTE buffer (IDT, Coralville, IA, USA) to a working concentration of 
30 ng/μ L, 0.6 pmol/μ L, 0.6 pmol/μ L, and 20 ng/μ L, respectively. The mixture was incubated at 37 °C for 5 minutes. 
One picoliter of the mixture was then injected into pronuclei of one-cell stage zygotes from C57BL/6 J mice (The 
Jackson Laboratory). Based on the published crystal structure, which reveals that Cas9, crRNA, tracrRNA and its 
DNA target forms a complex at a ratio of 1:1:1:125,26, we used equal molecular amounts of each component in the 
mixture. Based on a previous study2, we used 0.6 pmol/μ L of crRNA and tracrRNA for microinjection of mouse 
zygotes. To remain consistent with other reports27, we designed our donor DNA to be flanked on each side by ~50 
bases homologous to the sequence surrounding the Cas9-mediated DSB.
Oligo name Sequence
R257H-crRNA 5′ -gcuggagguuucagaaaggaGUUUUAGAGCUAUGCUGUUUUG-3′ 
tracrRNA 5′ -AAACAGCAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAAC UUGAAAAAGUGGCACCGAGUCGGUGCU-3′ 
R257H-DNA
5′ -GCAGAAGTTTCTGGATGACTATTCTCGCTTTGAAGACTGGCTGGA 
GGTTTCAGAAAGGACATCTGCTTTCCCCAGTTCTTCCGGGGTGCTCT 
ATACAGTTGCCAAGGAGGAGCTGAAGAAG-3′ 
ALPK2-crRNA 5′ -gaggugacuugguauaagaaGUUUUAGAGCUAUGCUGUUUUG-3′ 
PXN-L-crRNA 5′ -ggucuugucuguucacucugGUUUUAGAGCUAUGCUGUUUUG-3′ 
PXN-R-crRNA 5′ -uggcugcucuugcuggaggaGUUUUAGAGCUAUGCUGUUUUG-3′ 
PXN-L-DNA
5′ -TTCATAGCTCTGCTGCTCACAGGATGCTCCTAGTAATGTTAGGTCTTG 
TCTGTTCACTCTGATAACTTCGTATAGCATACATTATACGAAGTTATAGGT 
AGGGTCTCCCTCCACAGCCCGGACTGTTGTGGAACTCACTACGTAGTAA GCCTCTTC-3′ 
PXN-R-DNA
5′ -ATCAGGAGGCACGGACACAGGGACAAAGAGCCCTGTGTTGATGGCTGCT 
CTTGCTGGAGGAATAACTTCGTATAGCATACATTATACGAAGTTATGGGTGT 
GTCCTGCTGGGCCCGTGGGATCAGGATCCCAAGCCTGAGAGGTCACTTGCC CCAG-3′ 
Table 2.  Sequences of crRNA, tracrRNA, and single-strand oligodeoxynucleotides used in this study. 
ALPK, alpha kinase 2; PXN, paxillin.
Primer name Sequence GC% Tm
ALPK2-Forward(seq) TTAGCATATCCCATTGTGCTCATC 42 62
ALPK2-Reverse(seq) AATTACTAGTGTGCTATACTGTCTAG 35 61.7
SYNE1-R257H-F(wt) TGGAGGTTTCAGAAAGGACGG 52 61.2
SYNE1-R257H-F(mut) TGGAGGTTTCAGAAAGGACAT 43 57.5
SYNE1-R257H-F(rev) GCTAATCTTCAATTAAAATCGTCACTG 33 62.1
SYNE1-R257H-F(seq) TCCCTGGGCGGTTTGGGTC 68 63.6
OT1-Forward(seq) GCTGAGTGCGACTCCGTCC 68 63.6
OT1-Reverse(seq) GGCTAGGTGATAAGGCTCTAGC 55 64.2
OT2-Forward(seq) GTCTTTGGTCTATGTGTGATCATG 42 62
OT2-Reverse(seq) CAAAGACAGGTGCAGAACAGG 52 61.2
OT3-Forward(seq) GTGTAAGACATTGTGTGAAGTCCT 42 62
OT3-Reverse(seq) CTGTTGCTCACAGAGTCGCCA 57 63.2
OT4-Forward(seq) ATGGCATTGAAACCTTGTCAGCATA 40 62.5
OT4-Reverse(seq) ACCAGCCAGTGTGTAACCAGC 57 63.2
OT5-Forward(seq) GACAGTCACCGACTTGTAAAGC 50 62.1
OT5-Reverse(seq) CCCTGCCACTGTGCTATCATG 57 63.2
PXN-L-Forward(mut) AACGTGGTCACGAGCCCAGC 65 64.6
PXN-L-Reverse(mut) GACCCTACCTATAACTTCGTATAATG 38 62.9
PXN-R-Forward(mut) CATTCTTCGACCTCAGTTGAGTAG 46 63.6
PXN-R-Reverse(mut) GACACACCCATAACTTCGTATAAT 38 60.3
PXN-Forward(seq) TCACGGGATGAGACGACATAGG 55 64.2
PXN-Reverse(seq) GTGTTCTGAGGACAGCAAGCG 57 63.2
PXN-CRE-Forward TCCAGTGAGACCATGTAGTCCC 55 64
PXN-CRE-Reverse GCCCTATCAAGGCAATACATCTTC 46 63.6
Table 3.  Primers used in this study. ALPK, alpha kinase 2; SYNE1, nesprin-1α 2; OT, off-target; PXN, paxillin, 
Tm, melting temperature.
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PCR screening and sequence analysis. To prepare genomic DNA, mouse tails were incubated in 300 μ L 
of 50 mM NaOH at 98 °C for 30 minutes, then 50 μ L of 1 M Tris-HCl (pH 8.0) was added to the resultant solution. 
Genomic fragments at targets sites were amplified by PCR with Taq (NEB # E5000S) and two pairs of primers. All 
primers used in this study are listed in Table 3. The PCR conditions were as follows: 30 cycles of 94 °C for 20 sec-
onds, 60 °C for 20 seconds and 72 °C for 30 seconds. The resultant PCR amplicons were analyzed by electropho-
resis on a 2% agarose gel. For sequencing, PCR products were further sub-cloned using a Zero Blunt TOPO PCR 
cloning kit (Life Technologies, Grand Island, NY). The plasmid DNAs containing the genomic fragments were 
prepared from individual colonies. Six individual clones from each PCR reaction were sequenced.
T7 endonuclease I (T7E1) assay. The DNA fragment that overlaps the crRNA target site was amplified by 
PCR using the following primers: forward primer 5′ -AGGCTATTCTGTAGCTTCGCTC-3′ and reverse primer 5′ 
-CATTATCTGTCATTCAAGCCGTAAG-3′ The purified PCR product (~250 ng) was denatured and reannealed 
in NEB Buffer 2 (NEB) to form heteroduplex DNA, which was subsequently digested with T7E1 (NEB, M0302L) 
at 37 °C for 15 minutes and analyzed on a 2% agarose gel.
Off-target candidates. Potential off-target sites were predicted using the algorithm determined by the 
Zhang laboratory (http://crispr.mit.edu/). The 23 bp off-target sequence included the PAM motif of the guide 
sequence as the algorithm allows more than 23 bp. The top five off-target candidate sites are listed in Fig. 4a.
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